Seattle Genetics Signs U.K. Partner | Chemical & Engineering News
Volume 89 Issue 38 | p. 17 | Concentrates
Issue Date: September 19, 2011

Seattle Genetics Signs U.K. Partner

Department: Business
Keywords: antibodies, cancer, drug conjugates

Seattle Genetics and Oxford BioTherapeutics will jointly discover antibody-drug conjugates for cancer. OBT will generate panels of monoclonal antibodies against tumor-specific antigens that will be screened for activity using Seattle Genetics’ technology. The companies will each have an equal number of alternating options to select resulting antibody-drug conjugates for further development. Each company will receive progress-dependent milestone payments and royalties on sales of any resulting products by the other partner.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment